Disease relevance of Choline magnesium trisalicylate

• Although mild transient hepatotoxicity associated with aspirin and other salicylates has been well documented, most commonly with high-dose treatment for rheumatologic disorders 112), we report a case of severe hypersensitivity hepatitis with striking tissue and peripheral eosinophilia after ingestion of choline magnesium trisalicylate [1].
• Twenty-six patients with painful, bony metastases were recruited into a randomized, double-blind, single dose, two-treatment, three-part crossover study of choline magnesium trisalicylate (CMT) and placebo [2].
• Twenty patients with end-stage head and neck cancer, unresponsive to either acetaminophen with codeine or oxycodone hydrochloride, were placed on a four-drug analgesic regimen consisting of methadone hydrochloride, Trilisate or acetaminophen, a tricyclic antidepressant, and, in most cases, hydroxyzine [3].
• An open evaluation of trilisate tablets in rheumatic diseases [4].

High impact information on Choline magnesium trisalicylate

• In 6 rheumatoid arthritis patients receiving choline magnesium trisalicylate, mean steady-state serum levels were the same, and the ranges of hourly mean concentrations during 8 and 12 hour dosage intervals were 19 to 27 mg/dl and 17 to 30 mg/dl, respectively [5].
• At equivalent salicylate doses and pH values, the induction of acute gastric mucosal haemorrhagic erosions in rats by ASA and choline magnesium trisalicylate (CMT), a new non-acetylated salicylate, with and without the potentiating damaging effect of taurodeoxycholic acid (TDCA) were compared [6].
• In one patient, platelet aggregation appeared to be affected by CMT and bleeding time became markedly prolonged after IPF therapy [7].
• We have compared the effects of acetyl salicylic acid (ASA, aspirin) and choline magnesium trisalicylate (CMT), a non-acetylated salicylate product, on platelet aggregation in human whole blood ex-vivo [8].
• Claims that twice-daily dosage of choline magnesium trisalicylate (CMT) may alter salicylate disposal kinetics and result in sustained plasma levels were examined [9].

Biological context of Choline magnesium trisalicylate

• Choline magnesium trisalicylate does not impair platelet aggregation [10].

Anatomical context of Choline magnesium trisalicylate

• Endoscopic evaluation of the comparative effects of acetylsalicylic acid and choline magnesium trisalicylate on human gastric and duodenal mucosa [11].

Associations of Choline magnesium trisalicylate with other chemical compounds

• A comparison of choline magnesium trisalicylate and acetylsalicylic acid in patients with rheumatoid arthritis [12].
• A double-blind study compared choline magnesium trisalicylate (Trilisate tablets, Purdue Frederick) (CMT) and ibuprofen (IPF) in the treatment of rheumatoid arthritis [13].

Analytical, diagnostic and therapeutic context of Choline magnesium trisalicylate

• We performed a double-blind, placebo-controlled, randomized cross-over study on the effect of choline magnesium trisalicylate (CMT, trilisate) pre-treatment on ASA-induced adverse reactions in nine patients [14].

References